Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Jul 29

PMID 37509464

Authors

Anasse Nounsi

Joseph Seitlinger

Charlotte Ponte

Julien Demiselle

Ysia Idoux-Gillet

Erwan Pencreach

Michele Beau-Faller

Veronique Lindner

Jean-Marc Balloul

Eric Quemeneur

Helene Burckel

Georges Noel

Anne Olland

Florence Fioretti

Pierre-Emmanuel Falcoz

Nadia Benkirane-Jessel

Guoqiang Hua

Affiliations

Soon will be listed here.

Abstract

Radiation therapy and platinum-based chemotherapy are common treatments for lung cancer patients. Several factors are considered for the low overall survival rate of lung cancer, such as the patient's physical state and the complex heterogeneity of the tumor, which leads to resistance to the treatment. Consequently, precision medicines are needed for the patients to improve their survival and their quality of life. Until now, no patient-derived tumoroid model has been reported to predict the efficiency of radiation therapy in non-small-cell lung cancer. Using our patient-derived tumoroid model, we report that this model could be used to evaluate the efficiency of radiation therapy and cisplatin-based chemotherapy in non-small-cell lung cancer. In addition, these results can be correlated to clinical outcomes of patients, indicating that this patient-derived tumoroid model can predict the response to radiotherapy and chemotherapy in non-small-cell lung cancer.

Citing Articles

The prognostic significance of lymph nodes in patients with pT1c33N0M0 non-small cell lung cancer: a retrospective study.

Yang W, Wang L PeerJ. 2024; 12:e16866.

PMID: 38313027 PMC: 10838084. DOI: 10.7717/peerj.16866.

References

Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P . Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013; 3(6):630-5. PMC: 4160032. DOI: 10.1158/2159-8290.CD-13-0035. View

Moroni M, Maeda D, Whitnall M, Bonner W, Redon C . Evaluation of the gamma-H2AX assay for radiation biodosimetry in a swine model. Int J Mol Sci. 2013; 14(7):14119-35. PMC: 3742235. DOI: 10.3390/ijms140714119. View

Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L . Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Cell Stem Cell. 2019; 26(1):17-26.e6. DOI: 10.1016/j.stem.2019.10.010. View

Pasch C, Favreau P, Yueh A, Babiarz C, Gillette A, Sharick J . Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. Clin Cancer Res. 2019; 25(17):5376-5387. PMC: 6726566. DOI: 10.1158/1078-0432.CCR-18-3590. View

Yang L, Shen C, Estrada-Bernal A, Robb R, Chatterjee M, Sebastian N . Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair. Nucleic Acids Res. 2021; 49(19):11067-11082. PMC: 8565339. DOI: 10.1093/nar/gkab871. View

Di Liello R, Ciaramella V, Barra G, Venditti M, Della Corte C, Papaccio F . Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. ESMO Open. 2019; 4(4):e000536. PMC: 6735672. DOI: 10.1136/esmoopen-2019-000536. View

Karakasheva T, Gabre J, Sachdeva U, Cruz-Acuna R, Lin E, DeMarshall M . Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer. Sci Rep. 2021; 11(1):21304. PMC: 8556341. DOI: 10.1038/s41598-021-00706-8. View

Sundar S, Shakya S, Barnett A, Wallace L, Jeon H, Sloan A . Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma. Transl Oncol. 2021; 15(1):101251. PMC: 8551697. DOI: 10.1016/j.tranon.2021.101251. View

Hacker B, Rafat M . Organoids as Complex Models for Studying Radiation-Induced Cell Recruitment. Cell Mol Bioeng. 2020; 13(4):341-357. PMC: 7479086. DOI: 10.1007/s12195-020-00625-0. View

10.

Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J . Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004; 431(7008):525-6. DOI: 10.1038/431525b. View

11.

Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao A . Immunotherapy in lung cancer. Transl Lung Cancer Res. 2015; 3(1):53-63. PMC: 4367607. DOI: 10.3978/j.issn.2218-6751.2014.01.01. View

12.

Wang Y, Li Y, Sheng Z, Deng W, Yuan H, Wang S . Advances of Patient-Derived Organoids in Personalized Radiotherapy. Front Oncol. 2022; 12:888416. PMC: 9102799. DOI: 10.3389/fonc.2022.888416. View

13.

Chan B, Hughes B . Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015; 4(1):36-54. PMC: 4367711. DOI: 10.3978/j.issn.2218-6751.2014.05.01. View

14.

Seitlinger J, Nounsi A, Idoux-Gillet Y, Santos Pujol E, Le H, Grandgirard E . Vascularization of Patient-Derived Tumoroid from Non-Small-Cell Lung Cancer and Its Microenvironment. Biomedicines. 2022; 10(5). PMC: 9138465. DOI: 10.3390/biomedicines10051103. View

15.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

16.

Hubert C, Rivera M, Spangler L, Wu Q, Mack S, Prager B . A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res. 2016; 76(8):2465-77. PMC: 4873351. DOI: 10.1158/0008-5472.CAN-15-2402. View

17.

Bergethon K, Shaw A, Ou S, Katayama R, Lovly C, McDonald N . ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012; 30(8):863-70. PMC: 3295572. DOI: 10.1200/JCO.2011.35.6345. View

18.

Delom F, Begiristain I, Grenier T, Begueret H, Soulet F, Siegfried G . Patients Lung Derived Tumoroids (PLDTs) to model therapeutic response. Biochim Biophys Acta Mol Cell Res. 2020; 1867(11):118808. DOI: 10.1016/j.bbamcr.2020.118808. View

19.

Ray M, Jablons D, He B . Lung cancer therapeutics that target signaling pathways: an update. Expert Rev Respir Med. 2010; 4(5):631-45. PMC: 3031455. DOI: 10.1586/ers.10.64. View

20.

Li Z, Qian Y, Li W, Liu L, Yu L, Liu X . Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020; 23(8):101411. PMC: 7415928. DOI: 10.1016/j.isci.2020.101411. View